ASSOCIATION GENERALE DE L'INDUSTRIE DU MEDICAMENT - ALGEMENE VERENIGING VAN DE GENEESMIDDELENINDUSTRIE

Q: What is the address of ASSOCIATION GENERALE DE L'INDUSTRIE DU MEDICAMENT - ALGEMENE VERENIGING VAN DE GENEESMIDDELENINDUSTRIE?

The registered office of ASSOCIATION GENERALE DE L'INDUSTRIE DU MEDICAMENT - ALGEMENE VERENIGING VAN DE GENEESMIDDELENINDUSTRIE is located at Kantersteen 47, 1000 Brussel.

Q: Is ASSOCIATION GENERALE DE L'INDUSTRIE DU MEDICAMENT - ALGEMENE VERENIGING VAN DE GENEESMIDDELENINDUSTRIE still active?

Yes. According to the CBE (28 September 2026) ASSOCIATION GENERALE DE L'INDUSTRIE DU MEDICAMENT - ALGEMENE VERENIGING VAN DE GENEESMIDDELENINDUSTRIE is active, legal situation “Normale toestand”, started on 26 October 1966.

Q: Is ASSOCIATION GENERALE DE L'INDUSTRIE DU MEDICAMENT - ALGEMENE VERENIGING VAN DE GENEESMIDDELENINDUSTRIE registered on Peppol?

Yes, ASSOCIATION GENERALE DE L'INDUSTRIE DU MEDICAMENT - ALGEMENE VERENIGING VAN DE GENEESMIDDELENINDUSTRIE is registered on the Peppol network with ID 0208:0407622902.

Q: What is the enterprise number of ASSOCIATION GENERALE DE L'INDUSTRIE DU MEDICAMENT - ALGEMENE VERENIGING VAN DE GENEESMIDDELENINDUSTRIE?

The enterprise number of ASSOCIATION GENERALE DE L'INDUSTRIE DU MEDICAMENT - ALGEMENE VERENIGING VAN DE GENEESMIDDELENINDUSTRIE is BE0407622902.

Q: Who are the directors of ASSOCIATION GENERALE DE L'INDUSTRIE DU MEDICAMENT - ALGEMENE VERENIGING VAN DE GENEESMIDDELENINDUSTRIE?

According to the 2025 annual accounts, the directors of ASSOCIATION GENERALE DE L'INDUSTRIE DU MEDICAMENT - ALGEMENE VERENIGING VAN DE GENEESMIDDELENINDUSTRIE are: Sanofi Belgium NV, Almirall NV, Novartis Pharma NV, AstraZeneca NV, Amgen NV, Eli Lilly Benelux NV, MSD Belgium BVBA, Abbvie SA.

Q: Is ASSOCIATION GENERALE DE L'INDUSTRIE DU MEDICAMENT - ALGEMENE VERENIGING VAN DE GENEESMIDDELENINDUSTRIE a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 26 October 1966; 5 annual accounts filed, latest fiscal year 2025; 17 directors known from the annual account.

Q: What is the revenue of ASSOCIATION GENERALE DE L'INDUSTRIE DU MEDICAMENT - ALGEMENE VERENIGING VAN DE GENEESMIDDELENINDUSTRIE?

In its most recent annual accounts (2025), ASSOCIATION GENERALE DE L'INDUSTRIE DU MEDICAMENT - ALGEMENE VERENIGING VAN DE GENEESMIDDELENINDUSTRIE reported revenue of € 10,374,065.

Dossier ASSOCIATION GENERALE DE L'INDUSTRIE DU MEDICAMENT - ALGEMENE VERENIGING VAN DE GENEESMIDDELENINDUSTRIE, printed on 28 September 2026 from databakkes.be/en/0407622902/association-generale-de-l-industrie-du-medicament-algemene-vereniging-van-de-gen. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Financials

Financial year 2025

ASSOCIATION GENERALE DE L'INDUSTRIE DU MEDICAMENT - ALGEMENE VERENIGING VAN DE GENEESMIDDELENINDUSTRIE from Brussel, company number BE0407622902, closed financial year 2025 with a result of € 432,264 after tax. For that financial year ASSOCIATION GENERALE DE L'INDUSTRIE DU MEDICAMENT - ALGEMENE VERENIGING VAN DE GENEESMIDDELENINDUSTRIE recorded revenue of € 10.4 million and equity of € 6.7 million. Compared with financial year 2024, the result moved from € 289,650 to € 432,264. Profitable, and profit is growing. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on June 16, 2026.

What it is worth Growing

€ 6.7 million

▲ 7% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Growing

€ 432,264

▲ 49% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 4.8 million

▲ 38% vs 2024

Cash and bank balances on the last day of the fiscal year.

People and assets in 2025

Full-time equivalents

28.6

▲ 2.3 vs 2024

Average over the fiscal year, from the social balance sheet.

Wage cost Staff costs are payroll only. Director pay sits with services and miscellaneous goods: € 4.6 million in 2025, together with rent, insurance, accountants and other services. The accounts do not split that further.

€ 5.7 million

▲ 7% vs 2024

€ 197,700 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.

Vehicles and equipment

€ 95,684

▲ 13% vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt

None

No bank loans on the last day of the fiscal year.

Owed to suppliers

€ 684,890

▼ 2% vs 2024

Supplier invoices still open on the last day of the fiscal year. Pays suppliers within 54 days on average.

Taxes and wages

€ 1.1 million

▲ 3% vs 2024

Taxes, VAT and social contributions still to pay.

Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Revenue	€ 8,798,013 Revenue 2022: € 8,798,013 First fiscal year in the series	€ 9,771,280 Revenue 2023: € 9,771,280 ▲ 11% vs 2022 (€ 8,798,013) Favourable step	€ 9,946,202 Revenue 2024: € 9,946,202 ▲ 2% vs 2023 (€ 9,771,280) Favourable step	€ 10,374,065 Revenue 2025: € 10,374,065 ▲ 4% vs 2024 (€ 9,946,202) Favourable step	▲ 4%
Profit after taxes	€ 548,572 Profit after taxes 2022: € 548,572 First fiscal year in the series	€ 788,814 Profit after taxes 2023: € 788,814 ▲ 44% vs 2022 (€ 548,572) Favourable step	€ 289,650 Profit after taxes 2024: € 289,650 ▼ 63% vs 2023 (€ 788,814) Unfavourable step	€ 432,264 Profit after taxes 2025: € 432,264 ▲ 49% vs 2024 (€ 289,650) Favourable step	▲ 49%
Equity	€ 5,211,318 Equity 2022: € 5,211,318 First fiscal year in the series	€ 6,000,132 Equity 2023: € 6,000,132 ▲ 15% vs 2022 (€ 5,211,318) Favourable step	€ 6,289,782 Equity 2024: € 6,289,782 ▲ 5% vs 2023 (€ 6,000,132) Favourable step	€ 6,722,046 Equity 2025: € 6,722,046 ▲ 7% vs 2024 (€ 6,289,782) Favourable step	▲ 7%
Total debts	€ 1,363,833 Total debts 2022: € 1,363,833 First fiscal year in the series	€ 1,760,114 Total debts 2023: € 1,760,114 ▲ 29% vs 2022 (€ 1,363,833) Unfavourable step	€ 2,212,716 Total debts 2024: € 2,212,716 ▲ 26% vs 2023 (€ 1,760,114) Unfavourable step	€ 2,534,739 Total debts 2025: € 2,534,739 ▲ 15% vs 2024 (€ 2,212,716) Unfavourable step	▲ 15%
Cash	€ 3,248,608 Cash 2022: € 3,248,608 First fiscal year in the series	€ 4,069,982 Cash 2023: € 4,069,982 ▲ 25% vs 2022 (€ 3,248,608) Favourable step	€ 3,476,900 Cash 2024: € 3,476,900 ▼ 15% vs 2023 (€ 4,069,982) Unfavourable step	€ 4,798,179 Cash 2025: € 4,798,179 ▲ 38% vs 2024 (€ 3,476,900) Favourable step	▲ 38%
Retained profit	€ 3,068,009 Retained profit 2022: € 3,068,009 First fiscal year in the series	€ 3,856,823 Retained profit 2023: € 3,856,823 ▲ 26% vs 2022 (€ 3,068,009) Favourable step	€ 4,146,473 Retained profit 2024: € 4,146,473 ▲ 8% vs 2023 (€ 3,856,823) Favourable step	€ 4,578,737 Retained profit 2025: € 4,578,737 ▲ 10% vs 2024 (€ 4,146,473) Favourable step	▲ 10%
Balance sheet total	€ 6,589,595 Balance sheet total 2022: € 6,589,595 First fiscal year in the series	€ 8,035,350 Balance sheet total 2023: € 8,035,350 ▲ 22% vs 2022 (€ 6,589,595) Unchanged	€ 8,503,023 Balance sheet total 2024: € 8,503,023 ▲ 6% vs 2023 (€ 8,035,350) Unchanged	€ 9,257,310 Balance sheet total 2025: € 9,257,310 ▲ 9% vs 2024 (€ 8,503,023) Unchanged	▲ 9%
Employees (FTE)	24.4 Employees (FTE) 2022: 24.4 First fiscal year in the series	24.9 Employees (FTE) 2023: 24.9 ▲ 0.5 vs 2022 (24.4) Unchanged	26.3 Employees (FTE) 2024: 26.3 ▲ 1.4 vs 2023 (24.9) Unchanged	28.6 Employees (FTE) 2025: 28.6 ▲ 2.3 vs 2024 (26.3) Unchanged	▲ 2.3

Key figures of ASSOCIATION GENERALE DE L'INDUSTRIE DU MEDICAMENT - ALGEMENE VERENIGING VAN DE GENEESMIDDELENINDUSTRIE, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to ASSOCIATION GENERALE DE L'INDUSTRIE DU MEDICAMENT - ALGEMENE VERENIGING VAN DE GENEESMIDDELENINDUSTRIE?

What happened at ASSOCIATION GENERALE DE L'INDUSTRIE DU MEDICAMENT - ALGEMENE VERENIGING VAN DE GENEESMIDDELENINDUSTRIE in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

2028 Almirall NV stepped down as director. NBB
2028 Amgen NV stepped down as director. NBB
2028 MSD Belgium BVBA stepped down as director. NBB
2028 Roche NV stepped down as director. NBB
2028 Novo Nordisk pharma stepped down as director. NBB
2028 UCB Pharma NV stepped down as director. NBB
2028 Takeda Belgium Nv stepped down as director. NBB
2027 Eli Lilly Benelux NV stepped down as director. NBB

In short

From € 548,572 profit in 2022 to € 432,264 profit in 2025.

Paid € 265 in corporate taxes since 2022.

Best year ever: 2023, with € 788,814 profit.

Pays suppliers within 54 days on average.

Original PDFs at the National Bank ↗

A new publication or filing at ASSOCIATION GENERALE DE L'INDUSTRIE DU MEDICAMENT - ALGEMENE VERENIGING VAN DE GENEESMIDDELENINDUSTRIE? We notify you, reason included.

Follow ASSOCIATION GENERALE DE L'INDUSTRIE DU MEDICAMENT - ALGEMENE VERENIGING VAN DE GENEESMIDDELENINDUSTRIE

Databakkes Pro

Know what changes at your customers, suppliers and competitors. Without reading an annual account.

Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.

Yes, I want that

See what a followed company gets: the De Lijn dossier

Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.

My folder 3 companies

De Lijn 8 June 2026 New annual account 2025

filed on 8 June 2026

What was left

€ 20 k ▼ 91%
Money in the bank

€ 178 k ▼ 98%

Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit